The Peptide Podcast

By: The Peptide Queen
Listen for free

  • Summary

  • The Peptide Podcast is on a mission to help people enjoy making decisions about their health and wellness. Staying informed with our SIMPLE, FAST, FUN approach. We keep you up-to-date on everything peptides. From disease management and prevention to performance health, anti-aging strategies, and more. We give you accurate, unbiased information so you can choose the peptides that suit YOU best. In our casual and easy-to-understand style, we’ll help you save time and energy for what matters most. About the host: Our experienced clinical pharmacist, The Peptide Queen, knows all too well that the internet is flawed, confusing, and hard to navigate. She has over 14 years of experience in retail, hospital, and specialty pharmacy, with certifications in peptide therapy, international travel medicine, immunization delivery, and pharmacogenomics. She’s passionate about helping you stay informed, save time, and feel less overwhelmed by the amount of information (or misinformation) on the internet.
    This website and its content are copyright of The Peptide Podcast - All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited.
    Show More Show Less
Alternative & Complementary Medicine Exercise & Fitness Hygiene & Healthy Living
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • GLP-1 Agonists for Chronic Kidney Disease (CKD)

    GLP-1 Agonists for Chronic Kidney Disease (CKD)
    Oct 29 2024
    Imagine a treatment that not only helps manage diabetes but also holds the potential to reverse kidney failure — what was once thought to be impossible. The recent FLOW study has remarkable groundbreaking evidence that GLP-1 receptor agonists can significantly improve kidney function in chronic kidney disease (CKD) patients. And while researchers try to understand the full implications of these findings, one thing is clear: the landscape of kidney disease treatment may never be the same again. In this podcast, we’ll dive into the results of the FLOW trial and explore what they may mean for people at risk for kidney failure. What are GLP-1 Agonists? GLP-1 (glucagon-like peptide-1) agonists are a class of drugs that mimic the effects of the natural hormone GLP-1. They enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, improving blood sugar control. Beyond their primary use in diabetes management, GLP-1 agonists have been studied for various conditions, including obesity and cardiovascular disease prevention. The Study Overview The FLOW trial, which stands for "Fasting and Long-acting GLP-1 Receptor Agonist in Patients with Chronic Kidney Disease," focused on the impact of GLP-1 receptor agonists, specifically semaglutide, on patients with chronic kidney disease (CKD) and type 2 diabetes (those most at risk for kidney failure). Researchers observed a remarkable trend: patients receiving semaglutide demonstrated stabilization of kidney function and signs of renal recovery. This was groundbreaking, as reversing kidney damage has long been considered a near-impossible feat. Study Objectives The primary goal was to determine whether treatment with GLP-1 receptor agonists could improve kidney outcomes in patients with CKD. Study Design Participants: The study enrolled >3500 adults with type 2 diabetes and CKD. Intervention: Participants were randomized to receive either semaglutide or a placebo. Primary Outcomes: The main outcomes included changes in glomerular filtration rate (GFR) and the incidence of major adverse kidney events (kidney failure- need for transplantation or dialysis). Key Findings Renal Function Improvement: Patients on semaglutide showed significant improvements in glomerular filtration rates (GFR), a key indicator of kidney function. Reduced Inflammation: The drugs appeared to lower levels of inflammatory markers associated with kidney damage, suggesting a protective effect. Metabolic Benefits: Improvements in blood sugar control and weight loss were also observed, contributing to overall health and potentially alleviating stress on the kidneys. Adverse Events: The treatment was generally well-tolerated, with a favorable safety profile. Ethical Considerations As the results began to emerge, the ethical landscape of the study shifted dramatically. The control group, which was not receiving semaglutide, was found to be at a significantly higher risk of kidney deterioration. With compelling evidence that the GLP-1 agonist was safe and potentially life-saving, the ethics committee determined withholding treatment from any participants was no longer justifiable. Consequently, the study was halted prematurely to allow all participants access to the medication, prioritizing patient welfare over the continuation of research under an inequitable framework. This decision underscores the ethical responsibility of researchers to ensure that all patients receive the best possible care, especially when clear benefits are identified. Implications for Future Research While the early termination of the study raises questions about the completeness of the data collected, it also opens new avenues for further research. The findings encourage more extensive clinical trials to explore the mechanisms behind the renal protective effects of GLP-1 agonists. Additionally, there is a growing interest in investigating these drugs' long-term effects on kidney health and their potential role in preventing disease progression. As further studies unfold, there is hope that GLP-1 agonists will become a standard part of kidney disease management, potentially transforming outcomes for millions affected by this condition. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey. Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.
    Show More Show Less
    5 mins
  • How GLP-1 Agonists May Improve NASH

    How GLP-1 Agonists May Improve NASH
    Oct 17 2024
    Have you heard of fatty liver disease? Well, fatty liver disease is just what it sounds like—it's when fat builds up in the liver and starts causing issues. The official name for it is “nonalcoholic fatty liver disease,” or NAFLD for short. Now, if that fat buildup leads to inflammation, it’s called “nonalcoholic steatohepatitis,” or NASH. The “nonalcoholic” part just means it’s not caused by alcohol, which can also lead to similar liver problems. NASH is a more severe liver disease compared to NAFLD. This is because inflammation in the liver can lead to cirrhosis (scarring or fibrosis of the liver) and liver failure. Fatty liver disease happens when there's too much fat in the liver, but we’re still figuring out what actually causes that buildup. We do know that carrying extra body fat can raise the risk, and how our bodies handle sugars and fats might play a role, too. It’s also more common in Hispanic people than in other racial groups. Additional risk factors include a larger waist size, type 2 diabetes, and metabolic syndrome. Most people with fatty liver disease don’t have any symptoms. These happen much later in people who have more severe liver disease. If and when symptoms do happen, some people experience jaundice (yellowing of the skin or eyes), fatigue, and abdominal swelling from fluid build-up (ascites). Weakness, weight loss, and nausea or vomiting can also occur. People usually find out they have fatty liver disease by chance, often during tests for something else. For instance, routine blood tests might reveal higher levels of liver enzymes like AST and ALT. The increasing prevalence of obesity and metabolic syndrome has made NASH a significant public health concern. However, recent research has highlighted glucagon-like peptide-1 (GLP-1) agonists as a promising therapeutic option for improving NASH. In this podcast, we’ll discuss how GLP-1 agonists work and the clinical evidence supporting their effectiveness in treating NASH. Understanding GLP-1 Agonists GLP-1 is an incretin hormone produced in the intestines that plays an important role in glucose metabolism. GLP-1 agonists, such as liraglutide and semaglutide, mimic the action of this hormone, leading to increased insulin secretion, decreased glucagon release, and reduced appetite. Originally developed for the treatment of type 2 diabetes, GLP-1 agonists have gained attention for their potential effects on liver health, particularly in NASH patients. How Do GLP-1 Agonists Work in NASH? Weight Loss and Appetite Regulation: One of the primary benefits of GLP-1 agonists is their ability to promote weight loss. Excess weight is a significant risk factor for NASH, and weight reduction can lead to improvements in liver histology and function. By decreasing appetite and increasing satiety, these medications can help patients achieve significant weight loss, which may directly improve liver health. Improved Insulin Sensitivity: GLP-1 agonists enhance insulin sensitivity and glucose metabolism. Improved insulin action can reduce hepatic fat accumulation, a key feature of NASH. These agents may help manage the underlying metabolic dysregulation associated with NASH by improving insulin resistance. Direct Liver Effects: Emerging evidence suggests that GLP-1 receptors exist in liver cells. Activation of these receptors may directly influence liver inflammation and fibrosis. GLP-1 agonists have been shown to reduce markers of liver inflammation and fibrosis in preclinical models, indicating a potential role in mitigating liver damage. Antioxidant Properties: GLP-1 has antioxidant effects, which can help reduce oxidative stress—a significant contributor to liver injury in NASH. By decreasing oxidative stress, GLP-1 agonists may protect liver cells from damage and promote better liver health. Clinical Study Findings Several clinical studies have explored the efficacy of GLP-1 agonists in treating NASH, with promising results: Liraglutide Study: In a randomized controlled trial, patients with NASH treated with liraglutide showed significant reductions in liver fat content and improved liver histology after 48 weeks. The study reported a reduction in necroinflammation and fibrosis scores, highlighting the potential of liraglutide as a therapeutic agent for NASH. Semaglutide Research: A recent trial involving semaglutide demonstrated notable improvements in liver fat content and metabolic parameters among participants with NASH. The study indicated that patients experienced a significant reduction in body weight, which correlated with improved liver function tests and reduced hepatic inflammation. Long-Term Benefits: Ongoing research examines the long-term effects of GLP-1 agonists on NASH progression and resolution. Early data suggest that sustained treatment can lead to lasting improvements in liver health, reinforcing the need for long-term management strategies in patients with NASH. GLP-1 agonists ...
    Show More Show Less
    6 mins
  • Switching From Semaglutide to Tirzepatide

    Switching From Semaglutide to Tirzepatide
    Oct 10 2024
    Someone might switch from semaglutide to tirzepatide to achieve greater weight loss or improve blood sugar control. Tirzepatide has been shown to be more effective for some people because it works on two different hormones, GLP-1 and GIP. This combination can lead to better results in managing weight and overall health. Additionally, if a person stops losing weight on semaglutide or isn't feeling as much appetite suppression, switching to tirzepatide could provide a new option, especially at higher doses. In this podcast, we’ll discuss the feedback from doctors and patients about switching from semaglutide to tirzepatide for weight loss. The experiences shared are quite varied. Here are some common themes based on what healthcare providers and patients reported. 1. Appetite Suppression Patients' Experiences: Some patients report weaker appetite suppression with tirzepatide compared to semaglutide. They mention that they felt more consistently full or experienced less "food noise" (persistent thoughts about food) with semaglutide. Others find tirzepatide equally or more effective at reducing hunger, especially at higher doses (10 mg to 15 mg). They note that their appetite was well-controlled after titrating to these higher doses. Clinicians' Observations: Many clinicians observe that tirzepatide’s appetite suppression is dose-dependent, with lower doses (5 mg) sometimes being less effective than semaglutide 2.4 mg, but higher doses (7.5 mg and up) providing stronger suppression. Some clinics report that patients may need more time on tirzepatide for the full appetite-suppressing effects to become noticeable. 2. Weight Loss: Patients' Experiences: Many patients experience greater or more rapid weight loss with tirzepatide, especially when titrated to higher doses (10 mg or more). Some report that they plateaued with semaglutide but started losing more weight after switching to tirzepatide. Others find that their weight loss slows down after switching to tirzepatide, particularly if their tirzepatide dose starts low (e.g., 2.5 or 5 mg), which may take time to match the effects of semaglutide 2.4 mg. Clinicians' Observations: Physicians often report that tirzepatide tends to lead to greater weight loss overall compared to semaglutide, especially when patients reach the higher doses (15 mg). However, individual variability plays a significant role, with some patients responding better to one medication over the other, depending on their metabolic profile and personal response to the medications. 3. Side Effects: Patients' Experiences: Patients commonly note that tirzepatide's side effects are similar to semaglutide, particularly stomach-related symptoms like nausea, vomiting, and diarrhea. However, these effects tend to lessen over time with both medications. On the other hand, some patients may experience more intense side effects with tirzepatide, especially during the titration phase. Clinicians' Observations: Clinics generally find that tirzepatide’s tolerability improves when the dose is titrated slowly, starting at 2.5 mg. Jumping directly to higher doses (5 mg or more) can increase the likelihood of nausea and other stomach-related side effects. Long-term side effect profiles are comparable between the two, but some clinics observe that tirzepatide's dual mechanism (GIP + GLP-1) might cause more initial stomach discomfort in certain patients. 4. Patient Preferences: Some patients prefer staying on semaglutide because it effectively curbs their hunger and controls cravings better, even if tirzepatide provides more weight loss. Others favor tirzepatide due to its better results in weight loss and overall improvements in metabolic health, especially once they reach higher doses. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey. Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.
    Show More Show Less
    5 mins

What listeners say about The Peptide Podcast

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available